JPRN-jRCT2080223341未知3 期
An Extension Study of CACZ885N2301, Multi-center, Open Label Study of Canakinumab in Japanese Patients With Periodic Fever Syndromes (TRAPS, HIDS, or crFMF)
ovartis Pharma K.K.0 个研究点目标入组 4 人开始时间: 2016年10月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 2age old 至 ot applicable（—）
- 性别
- All
入选标准
- •*Completed Epoch 4 of the CACZ885N2301 study in Japan before the approval of canakinumab in Japan
- •*Written informed consent. Parent or legal guardian's written informed consent and child's assent, if appropriate, are required before any assessment is performed for patients < 20 years of age
排除标准
- •*Any conditions or significant medical problems in which the investigator judges the patient should not enter this extension study
- •Other protocol defined inclusion/exclusion may apply
研究者
相似试验
已完成
3 期
An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever SyndromesPeriodic Fevers SyndromeNCT02911857Novartis Pharmaceuticals4
进行中（未招募）
不适用
Estudio de extensión del estudio principal CACZ885H2251, abierto, multicéntrico de 24 semanas de duración para evaluar la seguridad, tolerabilidad y eficacia de canakinumab (ACZ885) en pacientes con gota tratados con canakinumab a demanda - H2251E1EUCTR2009-012316-40-ESovartis Farmacéutica S.A320
进行中（未招募）
不适用
A controlled extension study of CACZ885H2357 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective - H2357E1Treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffectiveMedDRA version: 12.1Level: LLTClassification code 10018627Term: GoutEUCTR2010-018913-32-NLovartis Pharma Services AG200
进行中（未招募）
不适用
A randomized, controlled extension study of CACZ885H2356 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective - H2356E1Treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffectiveMedDRA version: 12.1Level: LLTClassification code 10018627Term: GoutEUCTR2009-017503-29-LTovartis Pharma Services AG200
进行中（未招募）
不适用
A randomized, controlled extension study of CACZ885H2356 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective - H2356E1Treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffectiveMedDRA version: 12.1Level: LLTClassification code 10018627Term: GoutEUCTR2009-017503-29-EEovartis Pharma Services AG200